Hannan, R.; Dohopolski, M.J.; Pop, L.M.; Mannala, S.; Watumull, L.; Mathews, D.; Gao, A.; Garant, A.; Arriaga, Y.E.; Bowman, I.;
et al. Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines 2022, 10, 1419.
https://doi.org/10.3390/biomedicines10061419
AMA Style
Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Mathews D, Gao A, Garant A, Arriaga YE, Bowman I,
et al. Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines. 2022; 10(6):1419.
https://doi.org/10.3390/biomedicines10061419
Chicago/Turabian Style
Hannan, Raquibul, Michael J. Dohopolski, Laurentiu M. Pop, Samantha Mannala, Lori Watumull, Dana Mathews, Ang Gao, Aurelie Garant, Yull E. Arriaga, Isaac Bowman,
and et al. 2022. "Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer" Biomedicines 10, no. 6: 1419.
https://doi.org/10.3390/biomedicines10061419
APA Style
Hannan, R., Dohopolski, M. J., Pop, L. M., Mannala, S., Watumull, L., Mathews, D., Gao, A., Garant, A., Arriaga, Y. E., Bowman, I., Chung, J.-S., Wang, J., Ariizumi, K., Ahn, C., Timmerman, R., & Courtney, K.
(2022). Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines, 10(6), 1419.
https://doi.org/10.3390/biomedicines10061419
